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At the end of 2012, 3 decades after the human immunodeficiency virus (HIV) was first identified, neither a cure
nor a fully preventive vaccine was available. Despite multiple efforts, the epidemic remains an exceptional public
health challenge. At the end of 2012, it was estimated that, globally, 35 million people were living with HIV, 2.3
million had become newly infected, and 1.6 million had died from AIDS-related causes. Despite substantial
prevention efforts and increases in the number of individuals on highly active antiretroviral therapy
(HAART), the epidemic burden continues to be high. Here, we provide a brief overview of the epidemiology
of HIV transmission, the work that has been done to date regarding HIV modeling in different settings around
the world, and how to finance the response to the HIV epidemic. In addition, we suggest discussion topics on
how to move forward with the prevention agenda and highlight the role of treatment as prevention (TasP) in
curbing the epidemic.
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EVOLUTION OF MODELING IN THE
CONTEXT OF TasP
Mathematical models that predict the course of the HIV
epidemic have evolved tremendously [1–5]. Most im-
provements in these models have been the result of clin-
ical trials and cohort and ecological studies that have
shown the efficacy and effectiveness of highly active an-
tiretroviral therapy (HAART) in suppressing viral load in
blood and sexual fluids and in decreasing morbidity and
mortality [6–9]. Thus, mathematical models now incor-
porate HIV viral load as the main driver of HIV trans-
mission. These models led the scientific community to
ask the question, “What will happen to the HIV epidemic
if we start treating more people [10–13]?”Montaner and
colleagues formally introduced the concept of using HIV
treatment to prevent transmission in 2006 [13].
In the context of treatment as prevention
(TasP), mathematical models have combined complex
individually based knowledge of the clinical and epide-
miological aspects of HIV disease in order to inform us
about how HIV spreads and to predict and understand
the long-term population-level impact of this epidemic.
As a result, these models are now useful when making
predictions and when comparing the effect of different
and complex interventions with different outcomes.
More recent models have focused on comparing the ef-
fects of different strategies within the TasP framework
in order to determine which combinations of interven-
tions will yield the most significant results in terms of
reducing the spread of the HIV epidemic [3, 12, 14, 15].
One of the biggest challenges for policymakers and
other stakeholders in public health is assessment of
the impact of TasP based on the results of mathematical
models. These models vary greatly based on the follow-
ing: type (eg, deterministic vs stochastic); overall as-
sumptions for behavioral parameters and impact on
HIV transmission (eg, type of sexual or drug use mix-
ing, size and duration of partnerships, effect of harm-
reduction initiatives); different stages of infectiousness
(eg, models based on viral load or on CD4 thresholds,
models that differentiate stages in the HIV natural his-
tory, models that focus on the role of primary infection
in HIV transmission); assumption for a reduction in
HIV transmission due to HAART (eg, based on the
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efficacy of clinical trials or on the link between viral load and
transmission probabilities); transmission probabilities (eg,
type of contact, effect of male circumcision); assumption for
HAART initiation criteria (eg, immediate vs based on CD4
cell count criteria); and assumptions for retention in care (eg,
models that allowed loss to follow-up vs those that did not).
Eaton and colleagues elegantly highlighted these issues by com-
paring 12 independent models that assessed the impact of TasP
in South Africa [2]. They showed that although all models indi-
cated that TasP had a positive impact on the reduction of HIV
transmission, the models varied considerably regarding their
structure and parametric assumptions. Consequently, the pre-
dicted impact on the reduction of HIV incidence varied from
35% to 54% in the short term and from 32% to 74% in the long
term. Based on results from that study and similar ones in the
literature, caution should be exercised when comparing results
across models and when making policy recommendations since
the parametric assumptions behind these models dictate the
models’ projections and their effects on the overall HIV epidemic.
We also stress that model scenarios should be realistic and
should consider barriers to the success of TasP. These barriers
include gaps in antiretroviral coverage, fragmented health sys-
tems, acceptability issues (among patients, providers, and deci-
sion-makers), community preparedness to adopt the strategy,
financial costs, structural components, and human rights.
Therefore, for these models to be relevant in informing
decision-making, it is important that researchers in diverse
fields collaborate to ensure that the results that originate from
these models are relevant. In addition, since estimates from
these models are very sensitive to their hypotheses and param-
eters, assumptions need to be sound and, whenever possible,
based on empirical data in order for the model results to be
valid.
In view of competing interventions that range from TasP
strategies to behavioral modification and biomedical interven-
tions, it is important that models consider how to optimize
the combination of preventive strategies and, in turn, maximize
their effectiveness in curbing growth of the HIV epidemic.
MOVING THE TasP AGENDA FORWARD
Based on the overwhelming effect of TasP, it became apparent
that we need to move from “does it work” to “how do we ex-
pand” this strategy. Unfortunately, HAART has been expanded
around the world too slowly and it is not keeping pace with the
growth of the epidemic. In 2013, the World Health Organiza-
tion (WHO) published treatment guidelines that recommend
that HIV-positive individuals in serodiscordant relationships
and those coinfected with tuberculosis and hepatitis B virus be
offered HAART regardless of CD4 cell count in order to prevent
HIV transmission [16]. Note that these same recommendations
were put forth in the treatment guidelines from the Internation-
al AIDS Society–USA and the US Department of Health and
Human Services in 2010 [7, 17]. It is important to emphasize
that different mathematical models showed not only how cru-
cial it is to engage more people into treatment but that we need
to do it more quickly in order to achieve the full benefit of this
strategy. Timely or early initiation of treatment is associated
with clinical and societal benefits [6].
Although the WHO moved in the right direction, its new
guidelines need to be more prescriptive and not rely on a coun-
try’s ability to implement these guidelines. To date, most coun-
tries are still debating whether to adjust the HAART eligibility
criterion based on CD4 cell count from 350 to 500 cells/mm3.
Meanwhile, as people wait for treatment, they are still at risk of
irreversible immunologic damage, premature mortality, acquisi-
tion of AIDS-defining illness and tuberculosis, and, ultimately,
transmission of their infection [18]. Politics and political un-
willingness are creating obstacles to the optimal implementation
of strategies to control the HIV epidemic. Consequently, public
health officials need to mobilize and move the TasP agenda for-
ward and show that it is possible to control the epidemic. Be-
cause these restrictive treatment guidelines are highly reliant
on the CD4 cell count criterion, in many countries with concen-
trated epidemics, it is difficult to reach minority populations at
high risk of acquiring HIV. When we find these individuals, it is
important that they be tested and engaged into treatment im-
mediately. In most cases, these individuals are not offered treat-
ment because they do not meet the HAART initiation criterion
based on CD4 cell count. Therefore, countries need to adopt
broader guidelines more quickly in order to reach these individ-
uals and many others who are not receiving care. Sadly, the
price of medication in these countries plays a key role in slowing
treatment expansion since several countries (mostly middle-in-
come) are subjected to trade agreements or belong to economic
blocks that have very rigid patent protection laws, little space for
price reduction negotiations, and several restrictions on access
to low-cost generics.
Despite the extraordinary preventive effect of TasP, there is
still skepticism regarding its potential to generate behavioral
disinhibition and drug resistance. Some studies have suggested
that the preventive impact of TasP can potentially be offset by
an increase in HIV risk behavior, often due to a reduced per-
ceived risk of transmitting or acquiring HIV [19].However, dif-
ferent cohorts of injection drug users have not consistently
shown changes in risk behavior since the widespread use of
HAART [20]. The other main concern regarding use of TasP
relates to the emergence of drug resistance [21], which is closely
associated with treatment failure due to poor adherence [7, 17,
22]. Consequently, it is important to stress that the success of
TasP will depend on an individual’s ability to adhere to his or
her daily regimens.
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ECONOMICS OF TasP
The year 2008 was marked by the beginning of a global eco-
nomic downturn and, as a result, there has been a major need
to do more with limited resources in order to meet the needs of
those affected by HIV. More than 5 years since the economic
crisis, we continue to struggle to meet the care and treatment
needs of millions of people living with HIV. In addition, uncer-
tainties remain regarding the global response to theHIVepidemic,
particularly with respect to the feasibility and sustainability of
different preventive strategies, especially TasP.
In the clinical setting, TasP has been shown, beyond a doubt,
to be cost effective in the prevention of morbidity and mortality.
At the public health level, different studies, especially mathe-
matical models, have shown that TasP is not only cost effective
but it is also cost saving, especially if aggressively implemented
[3, 5, 15].These studies led to modeling that used the Investment
Framework in 2011 in which the mathematical model com-
pared different prevention interventions for halting HIV trans-
mission [15]. The main goal of the Investment Framework was
to model different strategies for HIV prevention, treatment,
and care in order to determine which combination of interven-
tions would be the most effective and cost saving in averting
new HIV infections (all ages) and premature mortality. The
model estimated the yearly cost of achieving universal access
to HIV prevention, treatment, care, and support by 2015 to
be $22 billion. In addition, implementation of the Investment
Framework would avert 12.2 million new HIV infections and
7.4 million deaths from AIDS between 2011 and 2020 when
compared with continuation of current approaches and it
would result in 29.4 million life-years gained during the same
period [15].
More recently, the paradigm regarding the effect of TasP has
shifted from thinking of this strategy as “if we treat more people,
it will cost more and we will see a prevention benefit” to it
will be cost saving and it will benefit society at large, since indi-
viduals on treatment will have improved quality of life and be
able to return to the workforce and provide for their families.
In addition, children in households of HIV-infected adults
will be raised by their parents and they will have a chance to
go to school with their counterparts from non–HIV-infected
households [23, 24].Thus, it is time to move from cost-effective-
ness analysis to cost-benefit analysis, since the latter includes
benefits that may reflect the economic gains that are possible
when individuals are engaged early in antiretroviral treatment.
This type of economic modeling is termed “third-generation
economic modeling,” and the focus is not only on how many
dollars and lives we are saving by preventing new infections
but also on societal and household benefits via employment
gains due to higher labor productivity. In addition to employ-
ment gains, children of adults who are on HAART have a high-
er rate of school enrollment than the children of those off
treatment. However, prior to treatment initiation at low CD4
counts, individuals and their households often experience a pe-
riod of economic decline [23]. The scale-up of TasP would rep-
resent a departure from the current strategy of initiating
treatment after an individual experiences CD4 decline as well
as economic decline. As such, an important economic benefit
of TasP approaches could be the prevention of an economic de-
cline among HIV-infected individuals and their households.
Therefore, Ministries of Finance and Ministries of Health
should be aware of these secondary benefits when making deci-
sions on expanding access to antiretroviral treatment.
IMPLEMENTATION ISSUES
The HIV epidemic has had a significant negative impact on the
living standards of many individuals, households, and commu-
nities. When the concept of “HIV/AIDS exceptionalism” was
introduced, we observed a significant global response to curb
the impact of the epidemic. This concept originated from the
idea that in order to decrease the impact of the HIV epidemic,
a response that is above and beyond “normal” health interven-
tions would be needed. However, since HIV treatment has be-
come highly effective in preventing morbidity, mortality, and
HIV transmission, the exceptionalism of HIV/AIDS today is
that it is not receiving the attention it once did. Although we
were able to dramatically improve the global response to the ep-
idemic, a disproportionate number of individuals are still being
infected with HIV. Unfortunately, services and programs for
those affected by HIV are tremendously disconnected and high-
ly inefficient in engaging individuals into care and treatment.
To this end, strategies should consider task shifting, integration
of HIV care with other clinical services, targeting the role of
physicians to that of supervising and dealing with complex
cases in order to minimize costs, and implementing efficient
and effective retention methods.
We should focus on each step in the cascade of care in order
to maximize the effectiveness of TasP in reducing the number of
new infections [25]. Each step is subject to significant attrition,
with the aggregate loss from the cascade easily reaching more
than 50% [25]. Thus, to diminish disease burden and HIV
transmission, a combined effort of different players in the
healthcare system who can develop a comprehensive strategy
and identify gaps in the delivery of care to these individuals
will be needed. Modeling can help us to compare different strat-
egies that we can use to find the combination of interventions
that will be cost effective and have the biggest effect on dimin-
ishing the burden of HIV/AIDS. Starting with testing, it should
be given voluntarily and offered routinely in healthcare settings.
It is important that the community be involved since different
demonstration projects have shown that testing coverage can be
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increased from very low levels to almost 90% coverage in a
very short period and it can be done relatively inexpensively
(approximately $10 per person tested) [26]. Next, we need to
maximize referral, care initiation, and retention among sympto-
matic and asymptomatic individuals. Currently, projects are un-
derway to examine interventions such as testing and initiating
treatment immediately, to maximize retention into treatment
among individuals with high CD4 cell counts, and to identify
and address barriers to treatment retention. The third step is
to measure the effect of TasP on HIV incidence. In this step,
we need to analyze data from research studies and predictions
from modeling in order to determine whether viral load sup-
pression is indeed associated with HIV incidence decline.
Data should be gathered from community trials and national
surveillance systems [27].
In addition, behavioral economics and psychology can help
us tackle key issues in the implementation of TasP; these issues
should be addressed in mathematical models that assess the cost
effectiveness or cost benefit of different interventions. One of
the most successful interventions in this field is the role of
financial and nonfinancial incentives in motivating patients to
adhere to treatment [28]. Incentives are commonly used in
developed countries to reduce rates of obesity and smoking in
the general population, and these studies are becoming promi-
nent in developing countries. For HIV, provision of incentives
might be an effective strategy for increasing testing, maximizing
treatment adherence, and achieving viral suppression and reten-
tion into care. In addition, incentives can be used to keep indi-
viduals enrolled in risk-reduction initiatives that will increase
adherence and treatment retention. However, it is too early to
ascertain patients’ motivation to continue modifying their
behavior and to keep them in care once the incentives are
stopped, and concerns regarding these incentive-based pro-
grams remain.
In conclusion, we continue to face the individual and societal
burdens of HIV, and an unacceptable number of individuals are
being infected and dying prematurely. In the past 5 years, the
research community embraced the notion of using TasP to
not only decrease mortality and morbidity but also to decrease
HIV transmission. Because HAART has prolonged the lives of
many individuals, the health, social, and economic costs to treat
this population are likely to continue to increase. If the opera-
tional research field does not advance quickly, we will continue
to fail these individuals and to incur high costs within health-
care systems that already struggle to cope with the current
demand.
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